N/A
N=23
Dietary Nitrate and Physiological Aging
Aging
Bottom Line
View on ClinicalTrials.gov: NCT02593305 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Change in Carotid Chemosensitivity Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults — -0.13; -0.05; -0.10; -0.11 L/min/%SpO2
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Super Beets (Dietary_supplement); Super Beets Placebo (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Darren P Casey
- Primary completion
- Apr 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Carotid Chemosensitivity Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults |
-0.13; -0.05; -0.10; -0.11 | — |
| PRIMARY Change in Systolic Blood Pressure During Metaboreflex Testing Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults. |
19.2; 13; 16.1; 17 | — |
Summary
The main purpose/s of this study is to examine the effects of 4 weeks of dietary nitrate supplementation on peripheral chemoreceptor sensitivity, spontaneous baroreflex sensitivity, and blood pressure responsiveness to a variety of physiological stressors in older healthy adults. We will also examine the effect of dietary nitrate supplementation on measures of central artery stiffness and aortic blood pressure in older adults. Lastly, we will also recruit a group of young subjects in order to help characterize the age-related changes associated with the physiological outcome measures of the present study.
Eligibility Criteria
Two separate age groups were included.
Inclusion Criteria
- Healthy young adults 18-35 years of age (comparison group)
- Healthy older adults 60-85 years of age (intervention group)
Exclusion Criteria
- Hypertension, hyperlipidemia, current smoker or smoker within the last year, heart disease, diabetes, Chronic obstructive pulmonary disease, asthma, sleep apnea, Raynaud's disease, body mass index (BMI) > 30 kg/m2, allergy medication, clinical depression, autonomic disorders and other conditions or medications that might normally alter cardiovascular function, exercise tolerance, and/or blood pressure responses.
Data sourced from ClinicalTrials.gov (NCT02593305). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.